智通财经网·2025-11-10 13:57Core Viewpoint - MeiraGTx Holdings has entered into a strategic collaboration with Eli Lilly to develop and commercialize gene therapies for eye diseases, leading to a significant pre-market stock price increase of 13.22% [1] Group 1: Collaboration Details - The agreement grants Eli Lilly global exclusive rights to MeiraGTx's AAV-AIPL1 gene therapy project, targeting Leber Congenital Amaurosis Type 4 (LCA4), a severe hereditary retinal disease caused by a defect in the AIPL1 gene [1] - Eli Lilly will also gain rights to additional gene therapy technologies from MeiraGTx as part of the collaboration [1] Group 2: Financial Terms - MeiraGTx will receive a $75 million upfront payment and could earn over $400 million upon achieving certain milestones [1] - The company will also be eligible for tiered royalties from potential sales of the licensed products [1]